Symbols / CNSP
CNSP Chart
About
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.71M |
| Enterprise Value | -7.99M | Income | -13.07M | Sales | — |
| Book/sh | 17.25 | Cash/sh | 15.90 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | 0.00 | Forward P/E | -7.62 | PEG | — |
| P/S | — | P/B | 0.17 | P/C | — |
| EV/EBITDA | 0.61 | EV/Sales | — | Quick Ratio | 5.04 |
| Current Ratio | 5.82 | Debt/Eq | 0.31 | LT Debt/Eq | — |
| EPS (ttm) | 776.03 | EPS next Y | -0.39 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 17:00 | ROA | -85.59% |
| ROE | -197.11% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 574.58K |
| Shs Float | 523.81K | Short Float | 4.91% | Short Ratio | 0.45 |
| Short Interest | — | 52W High | 55.20 | 52W Low | 2.95 |
| Beta | 0.41 | Avg Volume | 37.60K | Volume | 8.44K |
| Target Price | $20.00 | Recom | None | Prev Close | $3.09 |
| Price | $2.97 | Change | -3.88% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$20.00
Mean price target
2. Current target
$2.97
Latest analyst target
3. DCF / Fair value
$-370.73
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.97
Low
$20.00
High
$20.00
Mean
$20.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-12 | up | Maxim Group | Hold → Buy | $20 |
| 2025-03-25 | down | Maxim Group | Buy → Hold | — |
- Brain cancer drug developer hires CFO, CTO and CBO in strategic reset - Stock Titan ue, 17 Feb 2026 13
- CNSP - CNS Pharmaceuticals Latest Stock News & Market Updates - Stock Titan Wed, 17 Dec 2025 08
- CNS Pharmaceuticals Announces Reverse Stock Split - Yahoo Finance Fri, 18 Jul 2025 07
- Behavioral Patterns of CNSP and Institutional Flows - Stock Traders Daily hu, 29 Jan 2026 16
- CNS Pharma Stock Up Over 30% - Nasdaq hu, 15 Jan 2026 08
- CNS Pharmaceuticals stock falls after CEO steps down - Investing.com Wed, 17 Dec 2025 08
- CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved - Stocktwits Fri, 16 May 2025 13
- symbol__ Stock Quote Price and Forecast - CNN Fri, 16 Feb 2024 17
- CNS Pharmaceuticals (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor - The Globe and Mail Wed, 14 May 2025 07
- CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven? - Yahoo Finance Wed, 26 Mar 2025 07
- Brain cancer drug developer taps new CEO with global track record - Stock Titan Wed, 17 Dec 2025 08
- Is CNS Pharmaceuticals Stock Rally Real? - StocksToTrade ue, 13 May 2025 07
- CNS Pharmaceuticals shares tumble after clinical trial results - Investing.com ue, 25 Mar 2025 07
- CNS Pharmaceuticals (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22 - The Globe and Mail Fri, 18 Jul 2025 07
- New CNS Pharmaceuticals CEO launches broad review built around lead cancer drug - Stock Titan ue, 27 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -14.84M | -18.83M | -15.26M | -14.47M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -14.86M | -18.85M | -15.27M | -14.50M |
| ReconciledDepreciation | 3.31K | 4.13K | 11.76K | 13.07K |
| EBITDA | -14.84M | -18.83M | -15.26M | -14.47M |
| EBIT | -14.84M | -18.84M | -15.27M | -14.49M |
| NetInterestIncome | 44.14K | 13.88K | -7.03K | -9.29K |
| InterestExpense | 16.12K | 13.80K | 7.03K | 9.29K |
| InterestIncome | 60.26K | 27.69K | 0.00 | |
| NormalizedIncome | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -14.86M | -18.85M | -15.27M | -14.50M |
| TotalExpenses | 14.90M | 18.87M | 15.27M | 14.49M |
| TotalOperatingIncomeAsReported | -14.90M | -18.87M | -15.27M | -14.49M |
| DilutedAverageShares | 117.80K | 207.00 | 53.00 | 31.00 |
| BasicAverageShares | 117.80K | 207.00 | 53.00 | 31.00 |
| DilutedEPS | -126.13 | -91.07K | -288.19K | -467.59K |
| BasicEPS | -126.13 | -91.07K | -288.19K | -467.59K |
| DilutedNIAvailtoComStockholders | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncomeCommonStockholders | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncome | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncomeIncludingNoncontrollingInterests | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncomeContinuousOperations | -14.86M | -18.85M | -15.27M | -14.50M |
| PretaxIncome | -14.86M | -18.85M | -15.27M | -14.50M |
| NetNonOperatingInterestIncomeExpense | 44.14K | 13.88K | -7.03K | -9.29K |
| InterestExpenseNonOperating | 16.12K | 13.80K | 7.03K | 9.29K |
| InterestIncomeNonOperating | 60.26K | 27.69K | 0.00 | |
| OperatingIncome | -14.90M | -18.87M | -15.27M | -14.49M |
| OperatingExpense | 14.90M | 18.87M | 15.27M | 14.49M |
| ResearchAndDevelopment | 9.29M | 14.10M | 9.30M | 9.81M |
| SellingGeneralAndAdministration | 5.61M | 4.77M | 5.97M | 4.68M |
| GeneralAndAdministrativeExpense | 5.61M | 4.77M | 5.97M | 4.68M |
| OtherGandA | 5.61M | 4.77M | 5.97M | 4.68M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 117.80K | 207.00 | 53.00 | 31.00 |
| ShareIssued | 117.80K | 207.00 | 53.00 | 31.00 |
| TotalDebt | 326.07K | 300.81K | 409.97K | 387.79K |
| TangibleBookValue | 6.18M | -4.43M | 8.13M | 6.16M |
| InvestedCapital | 6.50M | -4.13M | 8.54M | 6.55M |
| WorkingCapital | 6.13M | -4.54M | 7.64M | 4.88M |
| NetTangibleAssets | 6.18M | -4.43M | 8.13M | 6.16M |
| CommonStockEquity | 6.18M | -4.43M | 8.13M | 6.16M |
| TotalCapitalization | 6.18M | -4.43M | 8.13M | 6.16M |
| TotalEquityGrossMinorityInterest | 6.18M | -4.43M | 8.13M | 6.16M |
| StockholdersEquity | 6.18M | -4.43M | 8.13M | 6.16M |
| RetainedEarnings | -84.42M | -69.57M | -50.72M | -35.44M |
| AdditionalPaidInCapital | 90.60M | 65.13M | 58.85M | 41.60M |
| CapitalStock | 1.41K | 2.00 | 1.62K | 949.00 |
| CommonStock | 1.41K | 2.00 | 1.62K | 949.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.52M | 6.13M | 4.92M | 2.59M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 2.52M | 6.13M | 4.92M | 2.59M |
| CurrentDebtAndCapitalLeaseObligation | 326.07K | 300.81K | 409.97K | 387.79K |
| CurrentDebt | 326.07K | 300.81K | 409.97K | 387.79K |
| CurrentNotesPayable | 326.07K | 300.81K | 409.97K | 387.79K |
| PayablesAndAccruedExpenses | 2.20M | 5.83M | 4.51M | 2.21M |
| CurrentAccruedExpenses | 828.39K | 224.95K | ||
| Payables | 3.68M | 1.98M | ||
| AccountsPayable | 3.68M | 1.98M | ||
| TotalAssets | 8.70M | 1.70M | 13.05M | 8.76M |
| TotalNonCurrentAssets | 42.44K | 109.68K | 488.47K | 1.28M |
| NonCurrentPrepaidAssets | 36.43K | 104.75K | 482.81K | 929.69K |
| NonCurrentDeferredAssets | 0.00 | 334.14K | ||
| NetPPE | 6.00K | 4.93K | 5.66K | 16.11K |
| CurrentAssets | 8.66M | 1.59M | 12.56M | 7.48M |
| OtherCurrentAssets | 1.29M | 839.59K | 2.51M | 2.47M |
| CurrentDeferredAssets | 20.64K | 202.86K | 0.00 | |
| PrepaidAssets | 2.51M | 2.47M | ||
| Receivables | 882.54K | 0.00 | ||
| AccountsReceivable | 882.54K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 6.46M | 548.72K | 10.06M | 5.00M |
| CashAndCashEquivalents | 6.46M | 548.72K | 10.06M | 5.00M |
| CashFinancial | 548.72K | 10.06M | 5.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -17.12M | -14.14M | -10.56M | -13.54M |
| RepaymentOfDebt | -300.81K | -438.73K | -427.70K | -477.49K |
| IssuanceOfCapitalStock | 23.38M | 2.32M | 16.04M | 4.65M |
| CapitalExpenditure | -4.19K | -3.90K | -4.42K | -5.75K |
| InterestPaidSupplementalData | 13.60K | 13.80K | 8.09K | 9.77K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 6.46M | 548.72K | 10.06M | 5.00M |
| BeginningCashPosition | 548.72K | 10.06M | 5.00M | 14.04M |
| ChangesInCash | 5.91M | -9.51M | 5.05M | -9.03M |
| FinancingCashFlow | 23.03M | 4.64M | 15.61M | 4.51M |
| CashFlowFromContinuingFinancingActivities | 23.03M | 4.64M | 15.61M | 4.51M |
| NetOtherFinancingCharges | -66.75K | -202.86K | ||
| ProceedsFromStockOptionExercised | 21.32K | 2.96M | 2.73K | 332.75K |
| NetCommonStockIssuance | 23.38M | 2.32M | 16.04M | 4.65M |
| CommonStockIssuance | 23.38M | 2.32M | 16.04M | 4.65M |
| NetIssuancePaymentsOfDebt | -300.81K | -438.73K | -427.70K | -477.49K |
| NetShortTermDebtIssuance | -300.81K | -438.73K | -427.70K | -477.49K |
| ShortTermDebtPayments | -300.81K | -438.73K | -427.70K | -477.49K |
| NetLongTermDebtIssuance | -477.49K | |||
| LongTermDebtPayments | -477.49K | |||
| InvestingCashFlow | -4.19K | -3.90K | -4.42K | -5.75K |
| CashFlowFromContinuingInvestingActivities | -4.19K | -3.90K | -4.42K | -5.75K |
| NetPPEPurchaseAndSale | -4.19K | -3.90K | -4.42K | -5.75K |
| PurchaseOfPPE | -4.19K | -3.90K | -4.42K | -5.75K |
| OperatingCashFlow | -17.11M | -14.14M | -10.56M | -13.54M |
| CashFlowFromContinuingOperatingActivities | -17.11M | -14.14M | -10.56M | -13.54M |
| ChangeInWorkingCapital | -3.69M | 3.70M | 3.16M | -780.02K |
| ChangeInPayablesAndAccruedExpense | -3.63M | 1.32M | 2.30M | 740.26K |
| ChangeInAccruedExpense | 603.44K | -294.86K | ||
| ChangeInPayable | 1.70M | 1.04M | ||
| ChangeInAccountPayable | 1.70M | 1.04M | ||
| ChangeInPrepaidAssets | -59.97K | 2.38M | 860.45K | -1.52M |
| OtherNonCashItems | 596.30K | |||
| StockBasedCompensation | 838.96K | 1.01M | 1.20M | 1.72M |
| AssetImpairmentCharge | 0.00 | 334.14K | 0.00 | |
| DepreciationAmortizationDepletion | 3.31K | 4.13K | 11.76K | 13.07K |
| DepreciationAndAmortization | 3.31K | 4.13K | 11.76K | 13.07K |
| Depreciation | 3.31K | 4.13K | 11.76K | 13.07K |
| OperatingGainsLosses | -190.00 | 498.00 | 3.11K | |
| GainLossOnSaleOfPPE | -190.00 | 498.00 | 3.11K | 0.00 |
| NetIncomeFromContinuingOperations | -14.86M | -18.85M | -15.27M | -14.50M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CNSP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|